What is Elev8 Health?

A sophisticated, research-focused e-commerce platform offering premium analytical compounds, peptide research formulations, and transparent batch-specific quality documentation.

Research Brief Detail | Elev8 Health

Research Library

Elev8 Research Brief

Retatrutide: Triple-Receptor Agonism and Metabolic Research

An Elev8 Health editorial review of published scientific and regulatory literature.

Elev8 Health did not conduct the studies summarized below unless expressly stated otherwise. Research Briefs are educational summaries of third-party scientific literature and regulatory information.

Metabolism

Current Evidence Profile

Human Clinical Evidence

Substantial Investigational Evidence

FDA Approval

Development Phase

Phase 3 Clinical Development

Human research is presented for scientific and educational context only. Elev8 Health does not recommend that its products be used for anything other than laboratory research purposes, and does not recommend human or veterinary use of any kind.

Introduction

Retatrutide is an investigational peptide that activates the GIP receptor, the GLP-1 receptor and the glucagon receptor. It is being investigated extensively for obesity and metabolic disease.

Research Areas

GIP receptor signalingGLP-1 receptor signalingGlucagon receptor signalingBody weightGlycemic controlCardiometabolic risk

Mechanisms

Simultaneous agonism at three incretin- and glucagon-related receptors is being investigated for combined effects on appetite regulation, glycemic control and energy expenditure.

Human Evidence

A Phase 2 randomized trial published in the New England Journal of Medicine demonstrated substantial body-weight reductions during the study period. A separate Phase 2 trial studied retatrutide in adults with type 2 diabetes. Multiple Phase 3 TRIUMPH studies have subsequently evaluated retatrutide in obesity and related conditions.

Preclinical Evidence

Preclinical receptor pharmacology supported the multi-receptor development rationale.

Limitations

All published human research is investigational. Long-term outcome and safety characterization is still in progress, and findings describe the investigational compound as studied under trial protocols — not an Elev8 research product.

Safety & Regulatory

Retatrutide is not an FDA-approved drug. FDA states that retatrutide has not been found safe and effective for any condition and cannot currently be used in federal compounding pathways.

Conclusion

Retatrutide has one of the more developed investigational human evidence bases in the catalog while remaining unapproved and under active Phase 3 study.

Elev8 Research Editorial Team • Evidence reviewed: 2026-08-22

Selected Published Research

Human Clinical Evidence

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

New England Journal of Medicine • 2023

Studied

Evaluated investigational retatrutide in adults with obesity.

Findings

The trial reported substantial body-weight reductions during the study period compared with placebo.

Limitations

Phase 2 investigational research; retatrutide is not FDA approved and long-term outcome data were beyond the study scope.

Source: PMID 37366315 • DOI 10.1056/NEJMoa2301972

View on PubMed View DOI

Human Clinical Evidence

Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes

The Lancet • 2023

Studied

Evaluated investigational retatrutide in adults with type 2 diabetes.

Findings

The trial reported changes in glycemic and body-weight measures across studied dose groups.

Limitations

Investigational Phase 2 research in a specific clinical population.

Source: PMID 37385280 • DOI 10.1016/S0140-6736(23)01053-X

View on PubMed View DOI

Registered Clinical Trial

TRIUMPH-1 — Phase 3 Study of Retatrutide

ClinicalTrials.gov

Studied

Phase 3 evaluation of retatrutide in obesity.

Findings

Registered Phase 3 trial; status listed as completed as of 2026.

Source: NCT05929066

View Clinical Trial

Registered Clinical Trial

TRIUMPH-3 — Retatrutide in Obesity and Established Cardiovascular Disease

ClinicalTrials.gov

Studied

Phase 3 evaluation of retatrutide in obesity with established cardiovascular disease.

Source: NCT05882045

View Clinical Trial

Registered Clinical Trial

TRIUMPH-5 — Retatrutide Compared With Tirzepatide in Obesity

ClinicalTrials.gov

Studied

Direct clinical comparison of retatrutide and tirzepatide in obesity.

Source: NCT06662383

View Clinical Trial

FDA / Regulatory

FDA — Concerns with Unapproved GLP-1 Drugs

U.S. Food & Drug Administration

Findings

Retatrutide is investigational and has not been approved by FDA. FDA states it has not been found safe and effective for any condition and cannot currently be used in federal compounding pathways.

Source: FDA concerns with unapproved GLP-1 drugs

View FDA Source

Sources & References

Elev8 Research Briefs summarize independently published scientific and regulatory materials. Elev8 Health did not conduct these studies unless expressly stated. Findings reported in animal, cellular, investigational, or formulation-specific research should not be interpreted as established effects of an Elev8 product.